Siemens Pays $223.5 Million to ‘Swallow’ Novartis Diagnostics Division, Cancer Treatment Industry May See Major Changes!
Siemens Healthcare has agreed to acquire Novartis AG's diagnostics unit for $223.5 million, a move aimed at further strengthening its strength in cancer treatments. The acquisition involves the Advanced Accelerator Applications division that Novartis paid for in 2017, which operates the second largest network of cyclotrons in Europe and is critical to the development of PET scanning technology. With this transaction, Siemens Healthcare will be able to expand its PET radiopharma business in Europe, further consolidating its leading position in the imaging market. Especially in the diagnosis of cancers such as lung, breast and cervical cancer, Siemens Healthcare will have a stronger competitiveness.
Novartis decided to sell its diagnostics division because of its relatively low growth potential, while Siemens Healthcare's imaging division is one of its biggest revenue generators. According to the financial report of the last quarter, Siemens Healthcare's imaging division sales accounted for more than half of the group's total revenue. The acquisition will not only enhance Siemens Healthcare's business strength, but also enable Novartis to further focus on its core business areas.
In addition, Novartis and Siemens Healthcare will collaborate to enhance the supply of nuclear isotopes used in radiopharmaceuticals. This cooperation will help both sides achieve greater breakthroughs in the medical field. NVS shares rose in premarket trading following the announcement. According to the latest data on Monday, in pre-market trading, NVS shares were up 0.47% to $119.12, showing the market's positive reaction to the deal.
2026-10-28
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Exit! Why Did Clariant Divest Its Venezuelan Business at a “Low Price”?
-
Can the Manufacturing Sector Withstand Dow’s April Polyethylene Price Doubling?
-
Sinopec and LG Chem Sign Agreement to Jointly Develop Sodium-Ion Battery Materials
-
BASF's Intensified Moves from May to June: Plant Closures, Divestitures, and Transformation in Sync
-
Reducing to Refocus: Novo Nordisk’s 9,000-Job Cut and the Strategic Realignment in Pharma
-
Mitsubishi Chemical to Halt Production of Key Epoxy Resin Grades by 2027
-
Brazil’s SISPA Platform Signals a New Phase in Pesticide Registration
-
$14.5 Billion Solstice–Element Solutions Merger Abruptly Terminated Less Than Two Months After Announcement
-
Yulong Petrochemical’s 100,000-ton MMA Project Comes Online Amid a “Deep V-Shaped Rebound” — Opportunity or Hidden Risk?
-
Profit Crushed, Layoffs and Restructuring Follow: What WACKER Chemie’s 2025 Performance Reveals
Recommend Reading
-
RMB 240 Million! Wanhua Chemical Establishes Another Joint Venture in Binzhou
-
Evonik Supervisory Board Approves Executive Changes, Extends Kullmann’s Term to 2030
-
Iran Fully Halts Petrochemical Exports as the Middle East Supply System Faces Restructuring
-
SABIC Europe Sale Enters EU Review as AEQUITA Builds a Larger Petrochemical Platform
-
BASF’s 2025 Report Card—“The Profit Evaporation Act”: Behind the €6.6 Billion EBITDA Lies a Deliberate Strategic Retreat
-
Business Society October 15, 2026 Acrylonitrile Trend Analysis: Strong Consolidation
-
Positive Factors Support Rising Coking Coal Prices
-
Business Society’s Trend Analysis for Propylene Oxide on September 14, 2026: Volatile Fluctuations
-
Business Society October 15, 2026 LDPE Trend Analysis: Mild Correction
-
Supply-side disruptions persist, lithium carbonate prices continue to rise